Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Harvard Business School
Baxter
Dow
McKinsey

Last Updated: August 15, 2022

Investigational Drug Information for Rintatolimod


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Rintatolimod?

Rintatolimod is an investigational drug.

There have been 17 clinical trials for Rintatolimod. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2001.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Breast Neoplasms, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Roswell Park Cancer Institute, and AIM ImmunoTech Inc.

Recent Clinical Trials for Rintatolimod
TitleSponsorPhase
Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast CancerNational Cancer Institute (NCI)Phase 2
Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast CancerRoswell Park Cancer InstitutePhase 2
Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory MelanomaNational Cancer Institute (NCI)Phase 2

See all Rintatolimod clinical trials

Clinical Trial Summary for Rintatolimod

Top disease conditions for Rintatolimod
Top clinical trial sponsors for Rintatolimod

See all Rintatolimod clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Harvard Business School
Baxter
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.